Oral vitamin C supplementation failed to hit its primary efficacy endpoints in a phase 2 trial involving patients with clonal cytopenia of undetermined significance (CCUS) or lower-risk myeloid malignancies, though investigators observed unexpected signals regarding overall survival and inflammatory markers. Published in the journal Cancer, the EVITA trial evaluated whether high-dose supplements could modify pre-cancerous blood disorders.
In Plain English: The Clinical Takeaway
- Unproven Efficacy: Vitamin C supplements did not meet primary clinical endpoints in the phase 2 trial, meaning routine use for treating these conditions is not yet supported by clinical data.
- Survival and Inflammation Signals: Researchers noted exploratory signals regarding overall survival and shifts in inflammatory cytokines like interleukin-6, pointing toward potential biological activity in lower-risk disease.
- Gastrointestinal and Renal Risks: Regular high-dose consumption carries documented risks of diarrhea, esophagitis, acid reflux aggravation, and kidney stone formation.
Epigenetic Mechanisms and the Rationale Behind High-Dose Supplementation
To understand the biological plausibility of the EVITA trial, researchers look closely at cellular genetics and enzymatic pathways. Peter A. Jones, PhD, DSc (hon), a distinguished professor at the Van Andel Institute and co-senior author of the study, noted that vitamin C functions as a powerful epigenetic drug. In terms of its specific mechanism, the nutrient operates as a vital cofactor for TET2—a DNA demethylase that must be present to drive 5-methylcytosine oxidation, which represents the initial stage of active DNA demethylation, a pathway essential for blood stem cell differentiation.
TET2 loss-of-function mutations rank among the most common somatic alterations found in CCUS and clonal hematopoiesis. These mutations render affected cell clones particularly sensitive to vitamin C depletion. Investigators designed the trial after observing high rates of vitamin C deficiency in this patient population, alongside laboratory discoveries showing that TET2-dependent enhancer demethylation governs gene-expression timing during normal hematopoiesis. Early laboratory models demonstrated that supplementing cell cultures exposed to chemical carcinogens with vitamin C was sufficient to block the emergence of malignant cells entirely.
Inflammatory Cytokine Shifts and Survival Signals in the EVITA Trial
Led by Kirsten Grønbæk, MD, DMSc, of the University of Copenhagen, the EVITA trial evaluated oral vitamin C supplementation over a 12-month treatment window. While the primary endpoint was missed, the intervention successfully shifted inflammatory cytokines. Researchers observed alterations in interleukin-6 in a pattern associated with lower-risk disease states. Grønbæk noted that controlling inflammation constructively may play a role in the observed survival signal, though she emphasized that the exact mechanisms remain under investigation.
A notable temporal disconnect exists within the data. Clonal growth rates were assessed at the 12-month treatment mark, whereas the overall survival benefit accumulated over a substantially longer follow-up period. Because the trial was small, lacked a formal sample size calculation, and treated patients for only 12 months without survival as a protocol endpoint, investigators stress that these survival findings remain exploratory.
| Trial Parameter | EVITA Trial Data |
|---|---|
| Study Phase | Phase 2, Randomized, Placebo-Controlled |
| Primary Endpoint | Missed |
| Secondary/Exploratory Signals | Overall Survival, Interleukin-6 Shifts |
| Treatment Duration | 12 Months |
Contraindications & When to Consult a Doctor
Because dietary supplements are sold over the counter, oncology nurses and physicians must proactively screen patients for self-prescribed regimens. Clinical data from the trial highlighted distinct adverse events associated with high-dose oral vitamin C intake. Gastrointestinal events occurred more frequently among participants receiving the supplement, including diarrhea (5% vs 2%) and esophagitis (5% vs 0%).
As an additional clinical observation, medical attention became necessary for a kidney stone in a participant who had a prior medical history of stones, noting that any individuals with kidney stones during the preceding 12 months had not been allowed into the study. Clinicians recommend that patients experiencing gastritis or dyspepsia consider taking supplements with food. Anyone diagnosed with clonal cytopenia of undetermined significance or lower-risk myeloid malignancies who is considering high-dose vitamin C must disclose this use to their oncology care team.
Navigating Future Phase 3 Research and Clinical Transparency
Moving forward, establishing definitive clinical utility requires robust validation. Both Grønbæk and Jones agree that the observed overall survival signal justifies a larger, definitive trial. Grønbæk confirmed that all-cause mortality will serve as the primary endpoint in the planned phase 3 study, which will also aim to clarify how specific TET2 mutation subtypes influence therapeutic response.
Recruiting for a placebo-controlled phase 3 trial presents logistical challenges, primarily because patients maintain easy commercial access to over-the-counter supplements. Jones advocates for incorporating routine vitamin C measurements into standard clinical workups for these blood disorders, arguing that a gram-a-day regimen presents a manageable safety profile. Until phase 3 data confirm efficacy, healthcare providers urge absolute transparency regarding supplement use to safeguard patient health.
References
- Mikkelsen SU, Al-Mousawi A, Puglisi AB, et al. Oral vitamin C supplementation in patients with clonal cytopenia of undetermined significance or lower-risk myeloid malignancies: results from EVITA, a phase 2 randomized, placebo-controlled trial. Cancer. 2026;132(19):e70549. doi:10.1002/cncr.70549
- Tahiliani M, Koh KP, Shen Y, et al. Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science. 2009;324(5929):930-935. doi:10.1126/science.1170116
- Tulstrup M, Soerensen M, Hansen JW, et al. TET2 mutations are associated with hypermethylation at key regulatory enhancers in normal and malignant hematopoiesis. Nat Commun. 2021;12(1):6061. doi:10.1038/s41467-021-26093-2
Disclaimer: This article is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Patients should consult their primary oncologist or hematologist before altering supplement routines.
